1. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.
- Author
-
Eichenauer DA, Simhadri VL, von Strandmann EP, Ludwig A, Matthews V, Reiners KS, von Tresckow B, Saftig P, Rose-John S, Engert A, and Hansen HP
- Subjects
- ADAM Proteins immunology, ADAM Proteins metabolism, ADAM10 Protein, Amyloid Precursor Protein Secretases immunology, Amyloid Precursor Protein Secretases metabolism, Antibodies immunology, Antibodies pharmacology, CD30 Ligand immunology, CD30 Ligand metabolism, Calcimycin pharmacology, Calcium metabolism, Cell Line, Tumor, Humans, Ki-1 Antigen metabolism, Lymphoma enzymology, Membrane Proteins immunology, Membrane Proteins metabolism, Protein Kinase C metabolism, ADAM Proteins antagonists & inhibitors, Amyloid Precursor Protein Secretases antagonists & inhibitors, Immunotherapy methods, Ki-1 Antigen immunology, Lymphoma immunology, Lymphoma therapy, Membrane Proteins antagonists & inhibitors
- Abstract
CD30 is a transmembrane protein selectively overexpressed on many human lymphoma cells and therefore an interesting target for antibody-based immunotherapy. However, binding of therapeutic antibodies stimulates a juxtamembrane cleavage of CD30 leading to a loss of target antigen and an enhanced release of the soluble ectodomain of CD30 (sCD30). Here, we show that sCD30 binds to CD30 ligand (CD153)-expressing non-target cells. Because antibodies bind to sCD30, this results in unwanted antibody binding to these cells via sCD30 bridging. To overcome shedding-dependent damage of normal cells in CD30-specific immunotherapy, we analyzed the mechanism involved in the release. Shedding of CD30 can be enhanced by protein kinase C (PKC) activation, implicating the disintegrin metalloproteinase ADAM17 but not free cytoplasmic calcium. However, antibody-induced CD30 shedding is calcium dependent and PKC independent. This shedding involved the related metalloproteinase ADAM10 as shown by the use of the preferential ADAM10 inhibitor GI254023X and by an ADAM10-deficient cell line generated from embryonically lethal ADAM10(-/-) mouse. In coculture experiments, the antibody-induced transfer of sCD30 from the human Hodgkin's lymphoma cell line L540 to the CD30-negative but CD153-expressing human mast cell line HMC-1 was inhibited by GI254023X. These findings suggest that selective metalloproteinase inhibitors blocking antibody-induced shedding of target antigens could be of therapeutic value to increase the specificity and reduce side effects of immunotherapy with monoclonal antibodies.
- Published
- 2007
- Full Text
- View/download PDF